CLINICAL STUDY: INTERVENTIONAL CARDIOLOGY
Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting
Franz-Josef Neumann, MDa,
Willibald Hochholzera,
Gisela Pogatsa-Murray, MDa,
Albert Schömig, MDa and
Meinrad Gawaz, MDa
a Medizinische Klinik and Deutsches Herzzentrum, Technische Universität München, Munich, Germany. This study was supported in part by grants from MSD Sharp & Dohme, Haar, Germany, and from Accumetrics, San Diego, California
Manuscript received June 26, 2000;
revised manuscript received December 13, 2000,
accepted January 4, 2001.
Reprint requests and correspondence: Dr. Franz-Josef Neumann, Medizinische Klinik der Technischen Universität, Ismaningerstrasse 22, 81674 Munich, Germany
neumann{at}dhm.mhn.de
OBJECTIVES
We sought to investigate whether abciximab, tirofiban and eptifibatide achieve comparable antiplatelet effects with coronary stenting.
BACKGROUND
The glycoprotein (GP) IIb/IIIa antagonists abciximab, tirofiban and eptifibatide differ in chemical structure, binding site and pharmacokinetics.
METHODS
Sixty patients undergoing coronary stenting were randomly assigned to abciximab (bolus 0.25 mg/kg body weight, infusion 10 µg per min for 12 h), tirofiban (bolus 10 µg/kg, infusion 0.15 µg/kg per min for 72 h) or eptifibatide (bolus 180 µg/kg, infusion 2 µg/kg per min for 72 h). We took serial blood samples to analyze platelet function by using flow cytometry, turbidimetric aggregometry and the rapid platelet-function assay (RPFA).
RESULTS
As assessed by RPFA, platelet aggregation after 2 h of infusion was reduced to 5.9 ± 7.8% (mean ± SD) of baseline by abciximab, to 5.0 ± 5.4% by tirofiban and to 7.8 ± 7.1% by eptifibatide (p = 0.42). Turbidimetric aggregometry with adenosine diphosphate stimulation yielded similar results, whereas percent inhibition of platelet aggregation after thrombin receptor stimulation was 45.8 ± 16.8% with abciximab, 51.3 ± 17.6% with tirofiban and 52.9 ± 14.8% with eptifibatide (p = 0.37). Tirofiban and eptifibatide maintained their level of platelet inhibition during infusion. Flow cytometry revealed that the reduction in the monocyte-platelet interaction by abciximab, tirofiban and eptifibatide was not significantly different (20.0 ± 21.9%, 23.8 ± 18.2% and 21.0 ± 19.8%, respectively; p = 0.87).
CONCLUSIONS
Abciximab, tirofiban and eptifibatide, at currently recommended doses, achieved similar levels of inhibition of platelet aggregation and a similar reduction in the platelet–monocyte interaction.
|
Abbreviations and Acronyms
| | ADP | = adenosine diphosphate | | FITC | = fluorescein isothiocyanate | | GP | = glycoprotein | | mAB | = monoclonal antibody | | PE | = phycoerythrin | | RPFA | = rapid platelet-function assay | | TRAP | = thrombin receptor activating peptide |
|
This article has been cited by other articles:
|
|
|
|
 
D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, K. Dorrler, T. Morath, A. Schomig, A. Kastrati, and N. von Beckerath
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
Eur. Heart J.,
April 2, 2009;
30(8):
916 - 922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Geisler, C. Zurn, M. Paterok, K. Gohring-Frischholz, B. Bigalke, K. Stellos, P. Seizer, B. F. Kraemer, J. Dippon, A. E. May, et al.
Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy
Eur. Heart J.,
July 1, 2008;
29(13):
1635 - 1643.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T Geisler, M Kapp, K Gohring-Frischholz, K Daub, C Dosch, B Bigalke, H Langer, C Herdeg, and M Gawaz
Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease
Heart,
June 1, 2008;
94(6):
743 - 747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Geisler, H. Langer, M. Wydymus, K. Gohring, C. Zurn, B. Bigalke, K. Stellos, A. E. May, and M. Gawaz
Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation
Eur. Heart J.,
October 2, 2006;
27(20):
2420 - 2425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Tucci, M. T. Ganter, C. R. Hamiel, R. Klaghofer, A. Zollinger, and C. K. Hofer
Platelet function monitoring with the Sonoclot analyzer after in vitro tirofiban and heparin administration
J. Thorac. Cardiovasc. Surg.,
June 1, 2006;
131(6):
1314 - 1322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Svilaas, I. C.C. van der Horst, and F. Zijlstra
The role of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention for ST elevation myocardial infarction
Eur. Heart J.,
December 1, 2005;
26(23):
2479 - 2481.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Hochholzer, D. Trenk, D. Frundi, P. Blanke, B. Fischer, K. Andris, H.-P. Bestehorn, H. J. Buttner, and F.-J. Neumann
Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention
Circulation,
May 24, 2005;
111(20):
2560 - 2564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest,
September 1, 2004;
126(3_suppl):
234S - 264S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J R S Day, I S Malik, A Weerasinghe, M Poullis, I Nadra, D O Haskard, K M Taylor, and R C Landis
Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention
Heart,
July 1, 2004;
90(7):
794 - 799.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F.-J. Neumann, A. Kastrati, G. Pogatsa-Murray, J. Mehilli, H. Bollwein, H.-P. Bestehorn, C. Schmitt, M. Seyfarth, J. Dirschinger, and A. Schomig
Evaluation of Prolonged Antithrombotic Pretreatment ("Cooling-Off" Strategy) Before Intervention in Patients With Unstable Coronary Syndromes: A Randomized Controlled Trial
JAMA,
September 24, 2003;
290(12):
1593 - 1599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Lee, N. A. Herity, B. L. Hiatt, W. F. Fearon, M. Rezaee, A. J. Carter, M. Huston, D. Schreiber, P. M. DiBattiste, and A. C. Yeung
Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition With Tirofiban Before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial
Circulation,
March 25, 2003;
107(11):
1497 - 1501.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. B. Batchelor, T. R. Tolleson, Y. Huang, R. L. Larsen, R. M. Mantell, P. Dillard, M. Davidian, D. Zhang, W. J. Cantor, M. H. Sketch Jr, et al.
Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes: The COMPARE Trial
Circulation,
September 17, 2002;
106(12):
1470 - 1476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Kupatt, R. Wichels, J. Horstkotte, F. Krombach, H. Habazettl, and P. Boekstegers
Molecular mechanisms of platelet-mediated leukocyte recruitment during myocardial reperfusion
J. Leukoc. Biol.,
September 1, 2002;
72(3):
455 - 461.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. D. Aymong, M. J. Curtis, M. Youssef, M. M. Graham, L. Shewchuk, W. Leschuk, and T. J. Anderson
Abciximab Attenuates Coronary Microvascular Endothelial Dysfunction After Coronary Stenting
Circulation,
June 25, 2002;
105(25):
2981 - 2985.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.J. Brener and E.J. Topol
Epicardial versus microcirculatory dissociation
Eur. Heart J.,
February 2, 2002;
23(4):
274 - 276.
[Full Text]
[PDF]
|
|
|
|
